ArticleOpen medicine (Warsaw, Poland)2026
Secretory IgA and butyrate depletion in Southeast Chinese infants with cow's milk allergy: pathogenic link and diagnostic biomarker.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the clinical significance of fecal butyrate and SIgA as non-invasive biomarkers for CMPA diagnosis. Methods: 45 OFC-confirmed CMPA infants (0-24 months) and 45 healthy controls were enrolled. Fecal SIgA (ELISA/BCA) and butyrate (HPLC) were quantified. Analyses included: univariate and multivariable logistic regression (adjusting for age/weight/length), symptom correlation (Cow's Milk-related Symptom Score, CoMiSS), and ROC-based diagnostic validation. Results: CMPA infants showed lower SIgA (6.39 ± 2.79 vs. 11.31 ± 3.32 μg/mg; p<0.001) and butyrate (298.81 vs. 810.07 μg/g; p=0.009). Both were associated with CMPA risk and inversely correlated with symptom severity. SIgA combined with CoMiSS achieved superior diagnostic accuracy (AUC=0.909) vs. CoMiSS alone (ΔAUC=0.103, p=0.010). Butyrate with CoMiSS showed no significant improvement (ΔAUC=0.002, p=0.767). Conclusions: This study indicates that low fecal SIgA and butyrate are associated with CMPA, suggesting they may play a role in the disease. The SIgA-CoMiSS integrated workflow allows non-invasive diagnosis with improved accuracy, addressing some limitations of current OFC-based protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.